We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Fusion Antibodies Plc | LSE:FAB | London | Ordinary Share | GB00BDQZGK16 | ORD 4P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 3.40 | 3.30 | 3.50 | 3.40 | 3.40 | 3.40 | 194,648 | 07:40:36 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 2.9M | -2.6M | -0.0272 | -1.25 | 3.24M |
Date | Subject | Author | Discuss |
---|---|---|---|
21/9/2020 09:19 | Bounce off the 0.618 fib. Perfecto. Didnt think this chance would come back. | tidy 2 | |
21/9/2020 09:13 | took a few today as well - | tomboyb | |
21/9/2020 09:12 | Yes can only but small tranches but we have lots of interest. | tidy 2 | |
21/9/2020 09:09 | Topping up at this price | prince7652 | |
21/9/2020 09:08 | As you cab see from Friday trading and today it's just people with £500 to £1500 in general. It's so illiquid the MMs saw for to use above market size rules on 2 buys of 3k to 5k at £1.88 to report them an hour late. FAB has 25 mill share in issue 60% plus held in larger holdings. It will be chaos when serious buying kicks in on the back of the potential news to come. FAB have not really been shouting too much about it either, which is good. | superg1 | |
21/9/2020 09:04 | The Company is now offering these antigens on a commercial basis to companies and researchers worldwide. Unlike the PCR tests that are currently being used to identify the presence of COVID-19, Fusion's antigens are able to confirm recent past infections and determine levels of neutralising antibodies to COVID-19. This could be invaluable for disease modelling and public health policy, as it will assist in the determination of true transmission rates and case fatality rates.The Company has commenced use of these antigens to interrogate the Library for SARS-CoV-2 neutralising antibodies with a view to providing these as potential prophylactic and therapeutic candidates. | tidy 2 | |
21/9/2020 08:52 | It's nice chatting here getting the basic understanding sorted before what will be the inevitable arrival of the herd. I did check on twist and yes it did go up $1.5 bill in value on Covid antibody hype. | superg1 | |
21/9/2020 08:49 | Diverisfication It was mentioned many times over the weekend, still not on the radar and a big signpost top suggest antibodies on the way. It would be incredible if the big params didn't engage rapidly now with Fusion re Covid. So that news to come. There were a number of confided punters on 4D picking this up while the usual crew were oblivious. Based on the underlying business, the share price and they lack of big spending needed, this is the lowest risk of the lot with a high chance of a good return without Covid in play. Obviously there is more news to come. | superg1 | |
21/9/2020 08:49 | Never read so much ramping. The current drop will continue as is typical in this type of share irrespective of what you say. Plenty of stock too as I got quote for £25K worth just now. | xtomo | |
21/9/2020 08:46 | I've topped up | tidy 2 | |
21/9/2020 08:46 | I like to keep an eye on the MMs. Wins still have some as they stepped over Shoc on the offer. | superg1 | |
21/9/2020 08:43 | Didn’t think I’d get an opportunity to buy more here. Just filled me boots. Unless I’m missing something, this is a perfect opportunity to add more prior to the therapeutic. | diversification | |
21/9/2020 08:40 | Bonus top up this am | tidy 2 | |
21/9/2020 08:36 | Roche, was the reason, another partnership. You will get a reply soon | amrishbhim | |
21/9/2020 08:32 | Wins clearly have some this morning. The usual crew like Myles will not say anything about it until they have some (if that's their plan) | superg1 | |
21/9/2020 08:32 | Gimme Going by linkedin they had the antigen success 2 months ago, so in theory the test results took 2 months but they could have cracked on with antibody generation in that time. This is not different to 4D it seemed largely missed that they had an almost identical answer like Synairgen. Synairgen was flying getting all the publicity while 4D sat around 50p. About £160 now when eventually the punters caught on. Both 4D and Syn are therapeutic options to recuse inflammation not stop covid. Fusion is the full range. I think they are the only share of the Covid crew that could produce the necessary antibodies to neutralise covid in the body, which is a much more exciting prospect. Literally test trace and eliminate, as they say. They can produce the answer to the lot. | superg1 | |
21/9/2020 08:30 | This dip will be short lived and a buying opportunity before we take off again | cbeadle | |
21/9/2020 08:10 | I think we will see money exiting Odx and coming into Fab looking at comparative market caps, a requirement to measure level of antibodies following a vaccine and the upside of a Neutralizing therapeutic to boot. | diversification | |
21/9/2020 08:03 | I have emailed FAB asking if the RNS in Friday relates to ROCHE which I am sure it’s does . I will post reply here once I receive. | gimmetheloot | |
21/9/2020 07:30 | No comment, anywhere, zilch! This is still under the radar, nothing on Twitter, ADVFN, Lse, today. Perfect. Low float of 9/10m shares will see this continue to fly imo. | diversification | |
21/9/2020 00:51 | This is a FAB & Roche collaboration deal. It’s simple. Same day same time RNS and FAB is a client of ROCHE. Both RNS are very very similar. | gimmetheloot | |
20/9/2020 23:14 | So putting 2 & 2 together and coming up with 5. It seems that with the Roche connections, they could have been one of the "external partners" referred to by Fusion that tested the antigens. Then on the same day that Roche announce their "new quantitative antibody test" and state that their test "targets antibodies against the spike protein" Fusion announce that “The Company has made progress on the design, expression and validation of SARS-CoV-2 proteins, commonly known as Coronavirus spike proteins” and “The Company’s extensive antigen manufacturing capabilities means that Fusion has been able to express high-purity antigens on a commercially viable scale for the development of diagnostic tests” Diversfication, I am just speculating, we know that FAB are working with 8 of the top 10 pharmas (if i recall correctly) Roche were 2nd biggest with $50B in March. I am just excited that if FAB are supplying them it means that as of now we are already supplying on a "commercial basis". Would love to know the commercial value probably never will know specifics, but if the connection is correct FAB have got off to a flying start. | 20pc | |
20/9/2020 22:36 | Perhaps the links to Roche has legs: Roche announce the Elecsys test at 06:03 on the 18th September. FAB put together an intraday RNS containing significant news at 09:31. Normally, significant updated such as trading updates, funding etc are well organized and announced at 07:00. My point being why intraday? Did Roche announcement force Fab hands? Would the fact that they are working with Roche require an RNS? Questions we need answering imo. | diversification |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions